Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 10/20 | 0.37 |
| ▸ | JAK1 | P23458 | 16/20 | 0.36 |
| ▸ | JAK2 | O60674 | 14/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 6/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4437639 | 0.91 | JAK3 (0.37) | JAK3JAK1JAK2CSF1RTYK2 | |
| SCHEMBL4441603 | 0.89 | BRD4 (0.33) | — | |
| SCHEMBL4448265 | 0.79 | HTR1A (0.31) | — | |
| SCHEMBL4440002 | 0.79 | JAK1 (0.39) | JAK3JAK1JAK2BRAF | |
| SCHEMBL4438467 | 0.79 | AAK1 (0.40) | JAK3JAK1JAK2BRAF | |
| SCHEMBL3647805 | 0.77 | JAK3 (0.38) | JAK3JAK1JAK2CSF1RTYK2 | |
| SCHEMBL3489438 | 0.75 | AKT2 (0.44) | JAK3 | |
| SCHEMBL3655001 | 0.72 | JAK1 (0.38) | JAK3JAK1JAK2TYK2BRAF | |
| SCHEMBL3652666 | 0.71 | AKT1 (0.38) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL3655831 | 0.71 | JAK1 (0.38) | JAK3JAK1JAK2TYK2BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125805-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | Astex Therapeutics Limited (GB) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008075109-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |